Renata Jachowicz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1255928/publications.pdf

Version: 2024-02-01

393982 329751 49 1,439 19 37 citations g-index h-index papers 50 50 50 1721 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Fused Deposition Modeling as a Possible Approach for the Preparation of Orodispersible Tablets. Pharmaceuticals, 2022, 15, 69.	1.7	9
2	Application and Multi-Stage Optimization of Daylight Polymer 3D Printing of Personalized Medicine Products. Pharmaceutics, 2022, 14, 843.	2.0	2
3	How Does Long-Term Storage Influence the Physical Stability and Dissolution of Bicalutamide from Solid Dispersions and Minitablets?. Processes, 2022, 10, 1002.	1.3	0
4	Modern solutions in the area of eye drops packaging. Farmacja Polska, 2022, 78, 201-208.	0.1	0
5	Minitablets as a dosage form convenient for pediatric and geriatric patients. Farmacja Polska, 2021, 76, 633-646.	0.1	0
6	How to Obtain the Maximum Properties Flexibility of 3D Printed Ketoprofen Tablets Using Only One Drug-Loaded Filament?. Molecules, 2021, 26, 3106.	1.7	10
7	The Impact of the Preparation Method on the Properties of Orodispersible Films with Aripiprazole: Electrospinning vs. Casting and 3D Printing Methods. Pharmaceutics, 2021, 13, 1122.	2.0	24
8	Prescription drug forms with midazolam. Farmacja Polska, 2021, 76, 711-715.	0.1	0
9	How Does the Addition of Kollidon®VA64 Inhibit the Recrystallization and Improve Ezetimibe Dissolution from Amorphous Solid Dispersions?. Pharmaceutics, 2021, 13, 147.	2.0	16
10	Nanofibers as a drug carrier in ophthalmic therapy. Farmacja Polska, 2021, 77, 690-696.	0.1	0
11	Orodispersible films containing ball milled aripiprazole-poloxamer®407 solid dispersions. International Journal of Pharmaceutics, 2020, 575, 118955.	2.6	30
12	Speed it up, slow it down…An issue of bicalutamide release from 3D printed tablets. European Journal of Pharmaceutical Sciences, 2020, 143, 105169.	1.9	41
13	How Does the CO2 in Supercritical State Affect the Properties of Drug-Polymer Systems, Dissolution Performance and Characteristics of Tablets Containing Bicalutamide?. Materials, 2020, 13, 2848.	1.3	2
14	Tabletting solid dispersions of bicalutamide prepared using ball-milling or supercritical carbon dioxide: the interrelationship between phase transition and <i>in-vitro</i> dissolution. Pharmaceutical Development and Technology, 2020, 25, 1109-1117.	1.1	4
15	Evolutionary Algorithms in Modeling Aerodynamic Properties of Spray-Dried Microparticulate Systems. Applied Sciences (Switzerland), 2020, 10, 7109.	1.3	0
16	Multivariate Design of 3D Printed Immediate-Release Tablets with Liquid Crystal-Forming Drug—ltraconazole. Materials, 2020, 13, 4961.	1.3	20
17	Compression-Induced Phase Transitions of Bicalutamide. Pharmaceutics, 2020, 12, 438.	2.0	13
18	Molecular Dynamics and Physical Stability of Ibuprofen in Binary Mixtures with an Acetylated Derivative of Maltose. Molecular Pharmaceutics, 2020, 17, 3087-3105.	2.3	9

#	Article	IF	CITATIONS
19	Data-Driven Modeling of the Bicalutamide Dissolution from Powder Systems. AAPS PharmSciTech, 2020, 21, 111.	1.5	9
20	Pharmaceutical industry before COVID-19. Farmacja Polska, 2020, 76, 269-274.	0.1	0
21	How can we improve the physical stability of co-amorphous system containing flutamide and bicalutamide? The case of ternary amorphous solid dispersions. European Journal of Pharmaceutical Sciences, 2019, 136, 104947.	1.9	22
22	The Self-Assembly Phenomenon of Poloxamers and Its Effect on the Dissolution of a Poorly Soluble Drug from Solid Dispersions Obtained by Solvent Methods. Pharmaceutics, 2019, 11, 130.	2.0	25
23	NEW TECHNOLOGICAL SOLUTIONS IN THE ASPECT OF TOPICAL AND ORAL ADMINISTRATION OF RESVERATROL. Farmacja Polska, 2019, 75, 599-604.	0.1	0
24	Orodispersible films (ODF) in individualized therapy. Farmacja Polska, 2019, 75, 568-574.	0.1	0
25	Lipid peroxidation in parenteral nutrition admixtures - prooxidative and antioxidative factors, as well as their clinical significance. Farmacja Polska, 2019, 75, 638-647.	0.1	1
26	Enhanced dissolution of solid dispersions containing bicalutamide subjected to mechanical stress. International Journal of Pharmaceutics, 2018, 542, 18-26.	2.6	17
27	Carrier optimization of pulmonary powder systems with using computational intelligence tools. Powder Technology, 2018, 329, 76-84.	2.1	3
28	Molecular Disorder of Bicalutamideâ€"Amorphous Solid Dispersions Obtained by Solvent Methods. Pharmaceutics, 2018, 10, 194.	2.0	15
29	3D printing of tablets containing amorphous aripiprazole by filaments co-extrusion. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 131, 44-47.	2.0	43
30	3D Printing in Pharmaceutical and Medical Applications $\hat{a}\in$ Recent Achievements and Challenges. Pharmaceutical Research, 2018, 35, 176.	1.7	428
31	3D printed orodispersible films with Aripiprazole. International Journal of Pharmaceutics, 2017, 533, 413-420.	2.6	182
32	Planetary ball milling and supercritical fluid technology as a way to enhance dissolution of bicalutamide. International Journal of Pharmaceutics, 2017, 533, 470-479.	2.6	36
33	Computational intelligence models to predict porosity of tablets using minimum features. Drug Design, Development and Therapy, 2017, Volume11, 193-202.	2.0	9
34	Effect of roll compaction on granule size distribution of microcrystalline cellulose–mannitol mixtures: computational intelligence modeling and parametric analysis. Drug Design, Development and Therapy, 2017, Volume11, 241-251.	2.0	13
35	Empirical search for factors affecting mean particle size of PLGA microspheres containing macromolecular drugs. Computer Methods and Programs in Biomedicine, 2016, 134, 137-147.	2.6	18
36	High energy ball milling and supercritical carbon dioxide impregnation as co-processing methods to improve dissolution of tadalafil. European Journal of Pharmaceutical Sciences, 2016, 95, 130-137.	1.9	25

3

#	Article	IF	Citations
37	Computational intelligence modeling of granule size distribution for oscillating milling. Powder Technology, 2016, 301, 1252-1258.	2.1	38
38	Transparent computational intelligence models for pharmaceutical tableting process. Complex Adaptive Systems Modeling, 2016, 4, .	1.6	8
39	Computational Intelligence Modeling of the Macromolecules Release from PLGA Microspheres—Focus on Feature Selection. PLoS ONE, 2016, 11, e0157610.	1.1	23
40	Empirical modeling of the fine particle fraction for carrier-based pulmonary delivery formulations. International Journal of Nanomedicine, 2015, 10, 801.	3.3	13
41	Development of <i>In VitroIn Vivo</i> <correlation "golem†a="" 1-13.<="" 2015,="" apparatus.="" approaches="" biomed="" compartmental="" data="" dissolution="" dynamic="" for="" formulations="" from="" immediate="" international,="" modeling="" novel="" relationship="" release="" research="" td="" using=""><td>0.9</td><td>8</td></correlation>	0.9	8
42	From Heuristic to Mathematical Modeling of Drugs Dissolution Profiles: Application of Artificial Neural Networks and Genetic Programming. Computational and Mathematical Methods in Medicine, 2015, 2015, 1-9.	0.7	17
43	Orodispersible films and tablets with prednisolone microparticles. European Journal of Pharmaceutical Sciences, 2015, 75, 81-90.	1.9	76
44	The practical approach to the evaluation of methods used to determine the disintegration time of orally disintegrating tablets (ODTs). Saudi Pharmaceutical Journal, 2015, 23, 437-443.	1.2	23
45	Heuristic modeling of macromolecule release from PLGA microspheres. International Journal of Nanomedicine, 2013, 8, 4601.	3.3	35
46	Application of artificial neural networks (ANNs) and genetic programming (GP) for prediction of drug release from solid lipid matrices. International Journal of Pharmaceutics, 2012, 436, 877-879.	2.6	11
47	KinetDS: An Open Source Software for Dissolution Test Data Analysis. Dissolution Technologies, 2012, 19, 6-11.	0.2	94
48	Analysis of pellet properties with use of artificial neural networks. European Journal of Pharmaceutical Sciences, 2010, 41, 421-429.	1.9	30
49	Neural network as a decision support system in the development of pharmaceutical formulationâ€"focus on solid dispersions. Expert Systems With Applications, 2005, 28, 285-294.	4.4	34